Xvivo Perfusion AB (LTS:0RKL) Total Current Assets : kr726.4 Mil (As of Mar. 2025)

View and export this data going back to 2016. Start your Free Trial

What is Xvivo Perfusion AB Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Xvivo Perfusion AB's total current assets for the quarter that ended in Mar. 2025 was kr726.4 Mil.

Xvivo Perfusion AB Total Current Assets Historical Data

The historical data trend for Xvivo Perfusion AB's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xvivo Perfusion AB Total Current Assets Chart

Xvivo Perfusion AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Current Assets

Get a 7-Day Free Trial

463.23

547.53

467.51

826.41

813.08

Xvivo Perfusion AB Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Total Current Assets	Get a 7-Day Free Trial															830.72	830.08	828.06	813.08	726.42

Xvivo Perfusion AB Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Xvivo Perfusion AB's Total Current Assets for the fiscal year that ended in Dec. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	415.521	+	132.117	+	227.406	+	38.032
	=	813.1

Xvivo Perfusion AB's Total Current Assets for the quarter that ended in Mar. 2025 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	315.871	+	184.67	+	225.875	+	1.1368683772162E-13
	=	726.4

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Xvivo Perfusion AB (LTS:0RKL) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Xvivo Perfusion AB's Liquidation Value for the quarter that ended in Mar. 2025 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	315.871	-	202.677	+	0.75 * 184.67	+	0.5 * 225.875
=	364.6

Xvivo Perfusion AB Total Current Assets Related Terms

Thank you for viewing the detailed overview of Xvivo Perfusion AB's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Xvivo Perfusion AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Xvivo Perfusion AB (LTS:0RKL) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

XVIPF:USA XVIVO:Sweden XVIVOs:UK 3XV:Germany

Address

Gemenskapens gata 9, Molndal, SWE, SE-431 53

Website

https://www.xvivoperfusion.com

Xvivo Perfusion AB is a medical technology company dedicated to extending the life of all of the majority organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments namely, Thoracic: Sales of lung and heart transplant products, Abdominal: Sales of liver and kidney transplant products. Services: Revenue from sales of services in organ recovery (carried out by subsidiary STAR Teams Inc.). The majority of revenue is derived from the Thoracic segment. Geographically, the majority is from the United States.

Xvivo Perfusion AB Headlines

No Headlines